Elevated SRPK1 lessens apoptosis in breast cancer cells through RBM4-regulated splicing events

RNA

Volumn 20, Issue 10, 2014, Pages 1621-1631

  Lin, Jung Chun ^a   Lin, Ching Yu ^a   Tarn, Woan Yuh ^b   Li, Fang Yu ^a  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

Alternative splicing; Breast cancer; MCL 1; RNA binding motif protein 4

Indexed keywords

CUPROUS ION; CYTOTOXIC AGENT; INSULIN RECEPTOR; MESSENGER RNA PRECURSOR; PROTEIN; PROTEIN MCL 1; RNA BINDING MOTIF PROTEIN 4; RNA BINDING PROTEIN; SERINE ARGININE PROTEIN KINASE 1; SERINE ARGININE RICH PROTEIN; UNCLASSIFIED DRUG; MCL1 PROTEIN, HUMAN; MESSENGER RNA; MYELOID LEUKEMIA FACTOR 1; PROTEIN SERINE THREONINE KINASE; RBM4 PROTEIN, HUMAN; SMALL INTERFERING RNA; SRPK1 PROTEIN, HUMAN;

ALTERNATIVE RNA SPLICING; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER LOCALIZATION; CARCINOGENESIS; CELL FRACTIONATION; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; CYTOPLASM; EXON; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE GENE; INTRON; MCF 7 CELL LINE; PROTEIN PHOSPHORYLATION; RNA BINDING; SENSITIVITY ANALYSIS; UPREGULATION; BREAST; BREAST TUMOR; CANCER GRADING; CANCER STAGING; CELL CULTURE; CELL PROLIFERATION; ENZYME IMMUNOASSAY; FEMALE; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PAGET NIPPLE DISEASE; PATHOLOGY; PHOSPHORYLATION; RNA SPLICING; TRANSCRIPTION INITIATION; TUMOR INVASION; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; BREAST; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL PROLIFERATION; CELLS, CULTURED; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RNA SPLICING; RNA, MESSENGER; RNA, SMALL INTERFERING; RNA-BINDING PROTEINS; TRANSCRIPTIONAL ACTIVATION;

EID: 84907225271     PISSN: 13558382     EISSN: 14699001     Source Type: Journal    
DOI: 10.1261/rna.045583.114     Document Type: Article

References (51)

1. Amin EM, Oltean S, Hua J, Gammons MV, Hamdollah-Zadeh M, Welsh GI, Cheung MK, Ni L, Kase S, Rennel ES, et al. 2011. WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing. Cancer Cell 20: 768-780.
2. Aubol BE, Plocinik RM, Hagopian JC, Ma CT, McGlone ML, Bandyopadhyay R, Fu XD. 2013. Partitioning RS domain phosphorylation in an SR protein through the CLK and SRPK protein kinases. J Mol Biol 425: 2894-2909.
3. Bae J, Leo C, Hsu S, Hsueh A. 2000. MCL-1S, a splicing variant of the antiapoptotic BCL-2 family member MCL-1, encodes a proapoptotic protein possessing only the BH3 domain. J Biol Chem 275: 25255-25261.
4. Ben-Hur V, Denichenko P, Siegfried Z, Maimon A, Krainer A, Davidson B, Karni R. 2013. S6K1 alternative splicing modulates its oncogenic activity and regulates mTORC1. Cell Rep 3: 103-115.
5. Bingle C, Craig R, Swales B, Singleton V, Zhou P, Whyte MK. 2000. Exon skipping in Mcl-1 results in a bcl-2 homology domain 3 only gene product that promotes cell death. J Biol Chem 275: 22136-22146.
6. Breig O, Baklouti F. 2013. Proteasome-mediated proteolysis of SRSF5 splicing factor intriguingly co-occurs with SRSF5 mRNA upregulation during late erythroid differentiation. PLoS One 8: e59137.
7. Brierley GV, Macaulay SL, Forbes BE, Wallace JC, Cosgrove LJ, Macaulay VM. 2010. Silencing of the insulin receptor isoform A favors formation of type 1 insulin-like growth factor receptor (IGF-IR) homodimers and enhances ligand-induced IGF-IR activation and viability of human colon carcinoma cells. Endocrinology 151: 1418-1427.
8. Burd CJ, Petre CE, Morey LM, Wang Y, Revelo MP, Haiman CA, Lu S, Fenoglio-Preiser CM, Li J, Knudsen ES, et al. 2006. Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation. Proc Natl Acad Sci 103: 2190-2195.
9. Chen J, WeissWA. 2014. Alternative splicing in cancer: implications for biology and therapy. Oncogene doi: 10.1038/onc.2013.570.
10. Chettouh H, Fartoux L, Aoudjehane L, Wendum D, Clapéron A, Chrétien Y, Rey C, Scatton O, Soubrane O, Conti F, et al. 2013. Mitogenic insulin receptor-A is overexpressed in human hepatocellular carcinoma due to EGFR-mediated dysregulation of RNA splicing factors. Cancer Res 73: 3974-3986.
11. Cohen-Eliav M, Golan-Gerstl R, Siegfried Z, Andersen CL, Thorsen K, Ørntoft TF, Mu D, Karni R. 2013. The splicing factor SRSF6 is amplified and is an oncoprotein in lung and colon cancers. J Pathol 229: 630-639.
12. Costa V, Foti D, Paonessa F, Chiefari E, Palaia L, Brunetti G, Gulletta E, Fusco A, Brunetti A. 2008. The insulin receptor: a new anticancer target for peroxisome proliferator-activated receptor-γ (PPARγ) and thiazolidinedione-PPARγ agonists. Endocr Relat Cancer 15: 325-335.
13. Das S, Anczuków O, Akerman M, Krainer AR. 2012. Oncogenic splicing factor SRSF1 is a critical transcriptional target of MYC. Cell Rep 1: 110-117.
14. Edmond V, Moysan E, Khochbin S, Matthias P, Brambilla C, Brambilla E, Gazzeri S, Eymin B. 2011. Acetylation and phosphorylation of SRSF2 control cell fate decision in response to cisplatin. EMBO J 30: 510-523.
15. Fregoso OI, Das S, Akerman M, Krainer AR. 2013. Splicing-factor oncoprotein SRSF1 stabilizes p53 via RPL5 and induces cellular senescence. Mol Cell 50: 56-66.
16. Gao J, Li L, Wu M, Liu M, Xie X, Guo J, Tang H, Xie X. 2013. MiR-26a inhibits proliferation and migration of breast cancer through repression of MCL-1. PLoS One 8: e65138.
17. Gautrey HL, Tyson-Capper AJ. 2012. Regulation of MCL-1 by SRSF1 and SRSF5 in cancer cells. PLoS One 7: e51497.
18. Gout S, Brambilla E, Boudria A, Drissi R, Lantuejoul S, Gazzeri S, Eymin B. 2012. Abnormal expression of the pre-mRNA splicing regulators SRSF1, SRSF2, SRPK1 and SRPK2 in non-small cell lung carcinoma. PLoS One 7: e46539.
19. Hayes GM, Carrigan PE, Beck AM, Miller LJ. 2006. Targeting the RNA splicing machinery as a novel treatment strategy for pancreatic carcinoma. Cancer Res 66: 3819-3827.
20. Hayes GM, Carrigan PE, Miller LJ. 2007. Serine-arginine protein kinase 1 overexpression is associated with tumorigenic imbalance in mitogen- activated protein kinase pathways in breast, colonic, and pancreatic carcinomas. Cancer Res 67: 2072-2080.
21. Iborra S, Hirschfeld M, Jaeger M, Zur Hausen A, Braicu I, Sehouli J, Gitsch G, Stickeler E. 2013. Alterations in expression pattern of splicing factors in epithelial ovarian cancer and its clinical impact. Int J Gynecol Cancer 23: 990-996.
22. Kalla Singh S, Brito C, Tan QW, De León M, De León D. 2011. Differential expression and signaling activation of insulin receptor isoforms A and B: a link between breast cancer and diabetes. Growth Factors 29: 278-289.
23. Kalli KR, Falowo OI, Bale LK, Zschunke MA, Roche PC, Conover CA. 2002. Functional insulin receptors on human epithelial ovarian carcinoma cells: implications for IGF-II mitogenic signaling. Endocrinology 143: 3259-3267.
24. Kozopas KM, Yang T, Buchan HL, Zhou P, Craig RW. 1993. MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc Natl Acad Sci 90: 3516-3520.
25. Krishnakumar S, Mohan A, Kandalam M, Ramkumar HL, Venkatesan N, Das RR. 2008. SRPK1: a cisplatin sensitive protein expressed in retinoblastoma. Pediatr Blood Cancer 50: 402-406.
26. Laha D, Pramanik A, Maity J, Mukherjee A, Pramanik P, Laskar A, Karmakar P. 2014. Interplay between autophagy and apoptosis mediated by copper oxide nanoparticles in human breast cancer cells MCF7. Biochim Biophys Acta 1840: 1-9.
27. Licatalosi DD, Darnell RB. 2010. RNA processing and its regulation: global insights into biological networks. Nat Rev Genet 11: 75-87.
28. Lin JC, Tarn WY. 2005. Exon selection in α-tropomyosin mRNA is regulated by the antagonistic action of RBM4 and PTB. Mol Cell Biol 25: 10111-10121.
29. Lin JC, Tarn WY. 2011. RBM4 down-regulates PTB and antagonizes its activity in muscle cell-specific alternative splicing. J Cell Biol 193: 509-520.
30. Lin JC, Hsu M, Tarn WY. 2007. Cell stress modulates the function of splicing regulatory protein RBM4 in translation control. Proc Natl Acad Sci 104: 2235-2340.
31. Lin JC, Tarn WY, Hsieh WK. 2014. Emerging role for RNA binding motif protein 4 in the development of brown adipocytes. Biochim Biophys Acta 1843: 769-779.
32. Manley JL, Krainer AR. 2010. A rational nomenclature for serine/arginine- rich protein splicing factors (SR proteins). Genes Dev 24: 1073-1074.
33. Merdzhanova G, Gout S, Keramidas M, Edmond V, Coll JL, Brambilla C, Brambilla E, Gazzeri S, Eymin B. 2010. The transcription factor E2F1 and the SR protein SC35 control the ratio of pro-angiogenic versus antiangiogenic isoforms of vascular endothelial growth factor-A to inhibit neovascularization in vivo. Oncogene 29: 5392-5403.
34. Mester J, Redeuilh G. 2008. Proliferation of breast cancer cells: regulation, mediators, targets for therapy. Anticancer Agents Med Chem 8: 872-885.
35. Moore MJ, Wang Q, Kennedy CJ, Silver PA. 2010. An alternative splicing network links cell-cycle control to apoptosis. Cell 142: 625-636.
36. Ngo JC, Chakrabarti S, Ding JH, Velazquez-Dones A, Nolen B, Aubol BE, Adams JA, Fu XD, Ghosh G. 2005. Interplay between SRPK and Clk/ Sty kinases in phosphorylation of the splicing factor ASF/SF2 is regulated by a docking motif in ASF/SF2. Mol Cell 20: 77-89.
37. Odunsi K, Mhawech-Fauceglia P, Andrews C, Beck A, Amuwo O, Lele S, Black JD, Huang RY. 2012. Elevated expression of the serine- arginine protein kinase 1 gene in ovarian cancer and its role in Cisplatin cytotoxicity in vitro. PLoS One 7: e51030.
38. Olshavsky NA, Comstock CE, Schiewer MJ, Augello MA, Hyslop T, Sette C, Zhang J, Parysek LM, Knudsen KE. 2010. Identification of ASF/SF2 as a critical, allele-specific effector of the cyclin D1b oncogene. Cancer Res 70: 3975-3984.
39. Palve VC, Teni TR. 2012. Association of anti-apoptotic MCL-1L isoform expression with radioresistance of oral squamous carcinoma cells. Radiat Oncol 7: 135.
40. Pennarun B, Kleibeuker JH, Boersma-van Ek W, Kruyt FA, Hollema H, de Vries EG, de Jong S. 2013. Targeting FLIP and MCL-1 using a combination of aspirin and sorafenib sensitizes colon cancer cells to TRAIL. J Pathol 229: 410-421.
41. Sen S, Talukdar I, Webster NJ. 2009. SRp20 and CUG-BP1 modulate insulin receptor exon 11 alternative splicing. Mol Cell Biol 29: 871-880.
42. Talukdar I, Sen S, Urbano R, Thompson J, Yates JR III, Webster NJ. 2011. hnRNP A1 and hnRNP F modulate the alternative splicing of exon 11 of the insulin receptor gene. PLoS One 6: e27869.
43. Uniacke J, Holterman CE, Lachance G, Franovic A, Jacob MD, Fabian MR, Payette J, Holcik M, Pause A, Lee S. 2012. An oxygenregulated switch in the protein synthesis machinery. Nature 486: 126-129.
44. Végran F, Boidot R, Bonnetain F, Cadouot M, Chevrier S, Lizard-Nacol S. 2011. Apoptosis gene signature of Survivin and its splice variant expression in breast carcinoma. Endocr Relat Cancer 18: 783-792.
45. Wang J, Smith PJ, Krainer AR, Zhang MQ. 2005. Distribution of SR protein exonic splicing enhancer motifs in human protein-coding genes. Nucleic Acids Res 33: 5053-5062.
46. Wang Y, Ma M, Xiao X, Wang Z. 2012. Intronic splicing enhancers, cognate splicing factors and context-dependent regulation rules. Nat Struct Mol Biol 19: 1044-1052.
47. Wang P, Zhou Z, Hu A, Ponte de Albuquerque C, Zhou Y, Hong L, Sierecki E, Ajiro M, Kruhlak M, Harris C, et al. 2014. Both decreased and increased SRPK1 levels promote cancer by interfering with PHLPP-mediated dephosphorylation of Akt. Mol Cell 54: 378-391.
48. Zhong XY, Ding JH, Adams JA, Ghosh G, Fu XD. 2009. Regulation of SR protein phosphorylation and alternative splicing by modulating kinetic interactions of SRPK1 with molecular chaperones. Genes Dev 23: 482-495.
49. Zhou Z, Fu XD. 2013. Regulation of splicing by SR proteins and SR protein- specific kinases. Chromosoma 122: 191-207.
50. Zhou Z, Qiu J, Liu W, Zhou Y, Plocinik RM, Li H, Hu Q, Ghosh G, Adams JA, Rosenfeld MG, et al. 2012. The Akt-SRPK-SR axis constitutes a major pathway in transducing EGF signaling to regulate alternative splicing in the nucleus. Mol Cell 47: 422-433.
51. Zhou B, Li Y, Deng Q, Wang H, Wang Y, Cai B, Han ZG. 2013. SRPK1 contributes to malignancy of hepatocellular carcinoma through a possible mechanism involving PI3K/Akt. Mol Cell Biochem 379: 191-199.